EquitySector - HealthcareVery High Risk
Direct
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹2,652 Cr
Expense Ratio
0.44%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.31%
+12.48% (Cat Avg.)
3 Years
+18.82%
+18.71% (Cat Avg.)
5 Years
+25.27%
+23.12% (Cat Avg.)
Since Inception
+22.13%
— (Cat Avg.)
Equity | ₹2,647.72 Cr | 99.83% |
Others | ₹4.51 Cr | 0.17% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹313.46 Cr | 11.82% |
Cipla Ltd | Equity | ₹195 Cr | 7.35% |
Aurobindo Pharma Ltd | Equity | ₹191.73 Cr | 7.23% |
Lupin Ltd | Equity | ₹167.51 Cr | 6.32% |
Divi's Laboratories Ltd | Equity | ₹162.42 Cr | 6.12% |
Glenmark Pharmaceuticals Ltd | Equity | ₹147.29 Cr | 5.55% |
Apollo Hospitals Enterprise Ltd | Equity | ₹141.98 Cr | 5.35% |
Dr Reddy's Laboratories Ltd | Equity | ₹119.91 Cr | 4.52% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹104.5 Cr | 3.94% |
Suven Pharmaceuticals Ltd | Equity | ₹93.93 Cr | 3.54% |
Torrent Pharmaceuticals Ltd | Equity | ₹87.42 Cr | 3.30% |
Syngene International Ltd | Equity | ₹82.52 Cr | 3.11% |
Gland Pharma Ltd | Equity | ₹82.14 Cr | 3.10% |
Wockhardt Ltd | Equity | ₹81.34 Cr | 3.07% |
Mankind Pharma Ltd | Equity | ₹78.52 Cr | 2.96% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹76.12 Cr | 2.87% |
Alkem Laboratories Ltd | Equity | ₹67.41 Cr | 2.54% |
Sai Life Sciences Ltd | Equity | ₹57.7 Cr | 2.18% |
Fortis Healthcare Ltd | Equity | ₹56.22 Cr | 2.12% |
OneSource Specialty Pharma Ltd | Equity | ₹53.15 Cr | 2.00% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹51.16 Cr | 1.93% |
Ipca Laboratories Ltd | Equity | ₹47.57 Cr | 1.79% |
Zydus Lifesciences Ltd | Equity | ₹42.53 Cr | 1.60% |
Biocon Ltd | Equity | ₹34.95 Cr | 1.32% |
Alembic Pharmaceuticals Ltd | Equity | ₹25.54 Cr | 0.96% |
Sagility India Ltd | Equity | ₹24.81 Cr | 0.94% |
Treps | Cash - Repurchase Agreement | ₹21.72 Cr | 0.82% |
Laxmi Dental Ltd | Equity | ₹20.11 Cr | 0.76% |
Neogen Chemicals Ltd | Equity | ₹19.62 Cr | 0.74% |
SRF Ltd | Equity | ₹19.42 Cr | 0.73% |
Net Receivables / (Payables) | Cash | ₹-17.43 Cr | 0.66% |
Suraksha Diagnostic Ltd | Equity | ₹1.75 Cr | 0.07% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.22 Cr | 0.01% |
Ajanta Pharma Ltd | Equity | ₹0.01 Cr | 0.00% |
Dr. Lal PathLabs Ltd | Equity | ₹0 Cr | 0.00% |
Large Cap Stocks
34.72%
Mid Cap Stocks
39.03%
Small Cap Stocks
23.32%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,608.68 Cr | 98.36% |
Basic Materials | ₹19.62 Cr | 0.74% |
Industrials | ₹19.42 Cr | 0.73% |
Standard Deviation
This fund
16.05%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.80
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.44% | Exit Load 1.00% | Fund Size ₹2,652 Cr | Age 6 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,97,449 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (21-Feb-25)
Returns (Since Inception)
Fund Size
₹2,652 Cr
Expense Ratio
0.44%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.31%
+12.48% (Cat Avg.)
3 Years
+18.82%
+18.71% (Cat Avg.)
5 Years
+25.27%
+23.12% (Cat Avg.)
Since Inception
+22.13%
— (Cat Avg.)
Equity | ₹2,647.72 Cr | 99.83% |
Others | ₹4.51 Cr | 0.17% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹313.46 Cr | 11.82% |
Cipla Ltd | Equity | ₹195 Cr | 7.35% |
Aurobindo Pharma Ltd | Equity | ₹191.73 Cr | 7.23% |
Lupin Ltd | Equity | ₹167.51 Cr | 6.32% |
Divi's Laboratories Ltd | Equity | ₹162.42 Cr | 6.12% |
Glenmark Pharmaceuticals Ltd | Equity | ₹147.29 Cr | 5.55% |
Apollo Hospitals Enterprise Ltd | Equity | ₹141.98 Cr | 5.35% |
Dr Reddy's Laboratories Ltd | Equity | ₹119.91 Cr | 4.52% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹104.5 Cr | 3.94% |
Suven Pharmaceuticals Ltd | Equity | ₹93.93 Cr | 3.54% |
Torrent Pharmaceuticals Ltd | Equity | ₹87.42 Cr | 3.30% |
Syngene International Ltd | Equity | ₹82.52 Cr | 3.11% |
Gland Pharma Ltd | Equity | ₹82.14 Cr | 3.10% |
Wockhardt Ltd | Equity | ₹81.34 Cr | 3.07% |
Mankind Pharma Ltd | Equity | ₹78.52 Cr | 2.96% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹76.12 Cr | 2.87% |
Alkem Laboratories Ltd | Equity | ₹67.41 Cr | 2.54% |
Sai Life Sciences Ltd | Equity | ₹57.7 Cr | 2.18% |
Fortis Healthcare Ltd | Equity | ₹56.22 Cr | 2.12% |
OneSource Specialty Pharma Ltd | Equity | ₹53.15 Cr | 2.00% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹51.16 Cr | 1.93% |
Ipca Laboratories Ltd | Equity | ₹47.57 Cr | 1.79% |
Zydus Lifesciences Ltd | Equity | ₹42.53 Cr | 1.60% |
Biocon Ltd | Equity | ₹34.95 Cr | 1.32% |
Alembic Pharmaceuticals Ltd | Equity | ₹25.54 Cr | 0.96% |
Sagility India Ltd | Equity | ₹24.81 Cr | 0.94% |
Treps | Cash - Repurchase Agreement | ₹21.72 Cr | 0.82% |
Laxmi Dental Ltd | Equity | ₹20.11 Cr | 0.76% |
Neogen Chemicals Ltd | Equity | ₹19.62 Cr | 0.74% |
SRF Ltd | Equity | ₹19.42 Cr | 0.73% |
Net Receivables / (Payables) | Cash | ₹-17.43 Cr | 0.66% |
Suraksha Diagnostic Ltd | Equity | ₹1.75 Cr | 0.07% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.22 Cr | 0.01% |
Ajanta Pharma Ltd | Equity | ₹0.01 Cr | 0.00% |
Dr. Lal PathLabs Ltd | Equity | ₹0 Cr | 0.00% |
Large Cap Stocks
34.72%
Mid Cap Stocks
39.03%
Small Cap Stocks
23.32%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,608.68 Cr | 98.36% |
Basic Materials | ₹19.62 Cr | 0.74% |
Industrials | ₹19.42 Cr | 0.73% |
Standard Deviation
This fund
16.05%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
0.80
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.56
Higher the better
Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.44% | Exit Load 1.00% | Fund Size ₹2,652 Cr | Age 6 years 8 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹27.99 Cr | 11.6% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.1% | 1.0% | ₹815.09 Cr | 6.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹815.09 Cr | 4.8% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹41.19 Cr | 9.0% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹216.51 Cr | 11.9% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹216.51 Cr | 9.8% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹2652.24 Cr | 12.3% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2652.24 Cr | 10.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹866.14 Cr | 8.2% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.92 Cr | 8.9% |
Total AUM
₹1,97,449 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments